Τίτλος:
First line gemcitabine/pazopanib in locally advanced and/or metastatic biliary tract carcinoma. A hellenic cooperative oncology group Phase II study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background/Aim: The efficacy of gemcitabinebased chemotherapy in locally advanced/metastatic biliary tract carcinoma is limited. The aim of this trial was to assess the activity of a novel gemcitabine-pazopanib combination in such patients. Patients and Methods: In this phase II, multicenter trial, patients with histologically/cytologically confirmed biliary tract carcinoma, previously untreated for advanced disease, received 1000 mg/m2 of gemcitabine on days 1 and 8 every 21 days and 800 mg of pazopanib once daily continuously for 8 cycles, followed by pazopanib maintenance. The primary endpoint was objective response rate (ORR). Results: A total of 29 patients (median age; 69 years) were enrolled between June 2013 and March 2018. The ORR was 13.8% in the intent-to-treat and 19.1% in the per protocol population. The median progression-free and overall survival were 6.3 and 10.4 months, respectively. Conclusion: The low response rate precludes further testing of the combination in patients with biliary tract carcinoma. © 2020 International Institute of Anticancer Research. All rights reserved.
Συγγραφείς:
Sgouros, J.
Aravantinos, G.
Koliou, G.-A.
Pentheroudakis, G.
Zagouri, F.
Psyrri, A.
Lampropoulou, D.I.
Demiri, S.
Pectasides, D.
Razis, E.
Fountzilas, G.
Samantas, E.
Περιοδικό:
ANTICANCER RESEARCH
Εκδότης:
International Institute of Anticancer Research
Λέξεις-κλειδιά:
gemcitabine; pazopanib; antineoplastic agent; deoxycytidine; gemcitabine; pazopanib; pyrimidine derivative; sulfonamide, acute kidney failure; adult; advanced cancer; aged; Article; bile duct carcinoma; bleeding; brain ischemia; clinical article; disease control; disease free survival; fatigue; female; human; human tissue; hypertension; lung abscess; male; multicenter study; overall survival; phase 2 clinical trial; priority journal; progression free survival; quality of life; bile duct cancer; clinical trial; metastasis; middle aged; treatment outcome; very elderly, Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome
DOI:
10.21873/anticanres.14026
